 | • レポートコード：TPM-B05045 • 出版社/出版日：Transparency Market Research / 2018年4月25日 • レポート形態：英文、PDF、194ページ • 納品方法：Eメール • 産業分類：Pharmaceutical |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、ギランバレー症候群の世界市場について調べ、ギランバレー症候群の世界規模、市場動向、市場環境、治療別（静脈内免疫グロブリン、血漿交換、その他）分析、投与経路別（経口、非経口）分析、販売チャネル別（院内薬局、小売薬局、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・ギランバレー症候群の世界市場動向 ・ギランバレー症候群の世界市場環境 ・ギランバレー症候群の世界市場規模 ・ギランバレー症候群の世界市場規模：治療別（静脈内免疫グロブリン、血漿交換、その他） ・ギランバレー症候群の世界市場規模：投与経路別（経口、非経口） ・ギランバレー症候群の世界市場規模：販売チャネル別（院内薬局、小売薬局、その他） ・ギランバレー症候群の世界市場：地域別市場規模・分析 ・ギランバレー症候群の北米市場規模・予測 ・ギランバレー症候群のアメリカ市場規模・予測 ・ギランバレー症候群のヨーロッパ市場規模・予測 ・ギランバレー症候群のアジア市場規模・予測 ・ギランバレー症候群の日本市場規模・予測 ・ギランバレー症候群の中国市場規模・予測 ・ギランバレー症候群のインド市場規模・予測 ・競争状況・関連企業情報 |
Guillain–Barré Syndrome Market – Overview
This report on the global Guillain–Barré syndrome market studies the current as well as future prospects of the market globally. Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain–Barré syndrome as well as new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain–Barré syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.
Based on therapeutics, the Guillain–Barré syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain–Barré syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain–Barré syndrome and available treatment options for Guillain–Barré syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain–Barré syndrome market and that could also influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies. The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain–Barré syndrome market.
Geographically, the global Guillain–Barré syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides the market size and forecast for major countries in the respective region. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain–Barré syndrome market.
Key players operating in the global Guillain–Barré syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.
The global Guillain–Barré syndrome market has been segmented as follows:
Global Guillain–Barré Syndrome Market, by Therapeutics
Intravenous Immunoglobulin
Plasma Exchange
Others (Analgesics, Anticonvulsants, LMWH, etc.)
Global Guillain–Barré Syndrome Market, by Route of Administration
Oral
Parenteral
Global Guillain–Barré Syndrome Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others (Home Care, Clinics, etc.)
Global Guillain–Barré Syndrome Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.
Rest of Europe
Asia Pacific
ASEAN
India
Japan
China
Rest of Asia Pacific
Rest of World
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Guillain–Barré Syndrome Market Size (US$ Mn) and Distribution, by Geography, 2017 and 2025
3.2. Global Guillain–Barré Syndrome Market Snapshot, 2016
3.3. Global Guillain–Barré Syndrome Market: Opportunity Map
4. Market Overview
4.1. Overview
4.2. Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, 2015–2025
4.3. Global Guillain–Barré Syndrome Market Outlook
4.4. Global Guillain–Barré Syndrome Market: Key Market Developments
4.5. Global Guillain–Barré Syndrome Market: Porter’s Five Forces
4.6. Global Guillain–Barré Syndrome Market: Key Success Factors of Top 3 Players
4.7. Guillain–Barré Syndrome: Disease Overview
4.7.1. Therapeutics
4.7.2. Epidemiology
4.7.3. Symptoms
4.7.4. Etiology
4.7.5. Pathophysiology
4.7.6. Diagnosis
4.8. Global Guillain–Barré Syndrome Market: Key Mergers & Acquisitions
4.9. Guillain–Barré Syndrome: Pipeline Analysis
4.10. Guillain–Barré Syndrome: Major Research Institutes Involved
5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunity Analysis
5.4. Opportunities
6. Guillain–Barré Syndrome Market Analysis, by Therapeutics
6.1. Introduction
6.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
6.3. Guillain–Barré Syndrome Market Analysis, by Therapeutics
6.3.1. Intravenous Immunoglobulin
6.3.2. Plasma Exchange
6.3.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
6.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics
7. Guillain–Barré Syndrome Market Analysis, by Route of Administration
7.1. Introduction
7.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
7.3. Guillain–Barré Syndrome Market Analysis, by Route of Administration
7.3.1. Oral
7.3.2. Parenteral
7.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration
8. Guillain–Barré Syndrome Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
8.3. Guillain–Barré Syndrome Market Analysis, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others (Home Care, Clinics, etc.)
8.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel
9. Guillain–Barré Syndrome Market Analysis, by Region
9.1. Global Guillain–Barré Syndrome Market Snapshot, by Country
9.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Region
9.3. Global Guillain–Barré Syndrome Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Rest of World
9.4. Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Region
9.5. Key Market Trends, by Region
10. North America Guillain–Barré Syndrome Market Analysis
10.1. Key Findings
10.2. North America Guillain–Barré Syndrome Market Overview
10.3. North America Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
10.4. North America Guillain–Barré Syndrome Market Forecast, by Therapeutics
10.4.1. Intravenous Immunoglobulin
10.4.2. Plasma Exchange
10.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
10.5. North America Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
10.6. North America Guillain–Barré Syndrome Market Forecast, by Route of Administration
10.6.1. Oral
10.6.2. Parenteral
10.7. North America Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
10.8. North America Guillain–Barré Syndrome Market Forecast, by Distribution Channel
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Others (Home Care, Clinics, etc.)
10.9. North America Guillain–Barré Syndrome Market Analysis, by Country
10.10. North America Guillain–Barré Syndrome Market Value Share Analysis, by Country
10.11. North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country, 2017–2025
10.11.1. U.S.
10.11.2. Canada
10.12. North America Guillain–Barré Syndrome Market Attractiveness Analysis
10.12.1. By Therapeutics
10.12.2. By Route of Administration
10.12.3. By Distribution Channel
10.12.4. By Country
11. Europe Guillain–Barré Syndrome Market Analysis
11.1. Key Findings
11.2. Europe Guillain–Barré Syndrome Market Overview
11.3. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
11.4. Europe Guillain–Barré Syndrome Market Forecast, by Therapeutics
11.4.1. Intravenous Immunoglobulin
11.4.2. Plasma Exchange
11.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
11.5. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
11.6. Europe Guillain–Barré Syndrome Market Forecast, by Route of Administration
11.6.1. Oral
11.6.2. Parenteral
11.7. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
11.8. Europe Guillain–Barré Syndrome Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Others (Home Care, Clinics, etc.)
11.9. Europe Guillain–Barré Syndrome Market Analysis, by Country/Sub-region
11.10. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Country/Sub-region
11.11. Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
11.11.1. U.K.
11.11.2. Germany
11.11.3. Italy
11.11.4. France
11.11.5. Spain
11.11.6. Rest of Europe
11.12. Europe Guillain–Barré Syndrome Market Attractiveness Analysis
11.12.1. By Therapeutics
11.12.2. By Route of Administration
11.12.3. By Distribution Channel
11.12.4. By Country/Sub-region
12. Asia Pacific Guillain–Barré Syndrome Market Analysis
12.1. Key Findings
12.2. Asia Pacific Guillain–Barré Syndrome Market Overview
12.3. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
12.4. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Therapeutics
12.4.1. Intravenous Immunoglobulin
12.4.2. Plasma Exchange
12.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.5. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
12.6. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Route of Administration
12.6.1. Oral
12.6.2. Parenteral
12.7. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
12.8. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Others (Home Care, Clinics, etc.)
12.9. Asia Pacific Guillain–Barré Syndrome Market Analysis, by Country/Sub-region
12.10. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Country/Sub-region
12.11. Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
12.11.1. China
12.11.2. Japan
12.11.3. India
12.11.4. ASEAN
12.11.5. Rest of Asia Pacific
12.12. Asia Pacific Guillain–Barré Syndrome Market Attractiveness Analysis
12.12.1. By Therapeutics
12.12.2. By Route of Administration
12.12.3. By Distribution Channel
12.12.4. By Country/Sub-region
13. Rest of World Guillain–Barré Syndrome Market Analysis
13.1. Key Findings
13.2. Rest of World Guillain–Barré Syndrome Market Overview
13.3. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
13.4. Rest of World Guillain–Barré Syndrome Market Forecast, by Therapeutics
13.4.1. Intravenous Immunoglobulin
13.4.2. Plasma Exchange
13.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.5. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
13.6. Rest of World Guillain–Barré Syndrome Market Forecast, by Route of Administration
13.6.1. Oral
13.6.2. Parenteral
13.7. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
13.8. Rest of World Guillain–Barré Syndrome Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Others (Home Care, Clinics, etc.)
13.9. Rest of World Guillain–Barré Syndrome Market Attractiveness Analysis
13.9.1. By Therapeutics
13.9.2. By Route of Administration
13.9.3. By Distribution Channel
14. Company Profiles
14.1. Global Guillain–Barré Syndrome Market Share Analysis, by Company, 2016
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Grifols S.A.
14.3.1.1. Company Details
14.3.1.2. Business Overview
14.3.1.3. Strategic Overview
14.3.1.4. SWOT Analysis
14.3.2. CSL Behring LLC
14.3.2.1. Company Details
14.3.2.2. Business Overview
14.3.2.3. Strategic Overview
14.3.2.4. SWOT Analysis
14.3.3. Shire plc
14.3.3.1. Company Details
14.3.3.2. Business Overview
14.3.3.3. Strategic Overview
14.3.3.4. SWOT Analysis
14.3.4. Octapharma AG
14.3.4.1. Company Details
14.3.4.2. Business Overview
14.3.4.3. Strategic Overview
14.3.4.4. SWOT Analysis
14.3.5. Nihon Pharmaceutical Co., Ltd.
14.3.5.1. Company Details
14.3.5.2. Business Overview
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. Akari Therapeutics, PLC
14.3.6.1. Company Details
14.3.6.2. Business Overview
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. China Biologic Products Holdings, Inc.
14.3.7.1. Company Details
14.3.7.2. Business Overview
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Biotest AG
14.3.8.1. Company Details
14.3.8.2. Business Overview
14.3.8.3. Strategic Overview
14.3.8.4. SWOT Analysis
14.3.9. Kedrion s.p.A.
14.3.9.1. Company Details
14.3.9.2. Business Overview
14.3.9.3. Strategic Overview
14.3.9.4. SWOT Analysis
TABLE 1 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 2 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 3 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 4 Global Guillain–Barré Syndrome Market Value (US$ Mn) Forecast, by Region, 2015–2025
TABLE 5 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country, 2015–2025
TABLE 6 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 7 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 8 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 9 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 10 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 11 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 12 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 13 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 14 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 15 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 16 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 17 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 18 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 19 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025